stoxline Quote Chart Rank Option Currency Glossary
  
Imunon, Inc. (IMNN)
1.45  0.05 (3.57%)    07-17 16:00
Open: 1.4
High: 1.52
Volume: 94,254
  
Pre. Close: 1.4
Low: 1.4
Market Cap: 14(M)
Technical analysis
2024-07-17 5:28:09 PM
Short term     
Mid term     
Targets 6-month :  1.77 1-year :  2.07
Resists First :  1.51 Second :  1.77
Pivot price 1.31
Supports First :  1.21 Second :  1.02
MAs MA(5) :  1.43 MA(20) :  1.25
MA(100) :  1.24 MA(250) :  1.05
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  88.4 D(3) :  91.3
RSI RSI(14): 63.9
52-week High :  2 Low :  0.47
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ IMNN ] has closed below upper band by 19.3%. Bollinger Bands are 18% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.52 - 1.53 1.53 - 1.54
Low: 1.38 - 1.39 1.39 - 1.4
Close: 1.44 - 1.45 1.45 - 1.46
Company Description

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.

Headline News

Mon, 24 Jun 2024
IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer - StockTitan

Mon, 24 Jun 2024
IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer - GlobeNewswire

Wed, 05 Jun 2024
First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial - Yahoo Finance

Mon, 13 May 2024
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Wed, 08 May 2024
Imunon Appoints Stacy R. Lindborg as New President and CEO - TipRanks

Thu, 18 Apr 2024
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101 - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 9 (M)
Shares Float 9 (M)
Held by Insiders 1.1 (%)
Held by Institutions 3.5 (%)
Shares Short 317 (K)
Shares Short P.Month 353 (K)
Stock Financials
EPS -2
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.89
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -45.1 %
Return on Equity (ttm) -107.3 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.14
Qtrly Earnings Growth 0 %
Operating Cash Flow -21 (M)
Levered Free Cash Flow -13 (M)
Stock Valuations
PE Ratio -0.73
PEG Ratio 0
Price to Book value 1.61
Price to Sales 0
Price to Cash Flow -0.66
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android